VYNE Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 1, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 1, 2024
YARW$15.79+1.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31 | ||
|---|---|---|
| 2023 | 2022 | |
| Assets | ||
| Current Assets: | ||
| Cash and cash equivalents | $30,620 | $30,908 |
| Restricted cash | 54 | 67 |
| Investment in marketable securities (Note 6) | 62,633 | — |
| Amount due from sale of MST Franchise | — | 5,000 |
| Prepaid and other current assets | 2,656 | 2,300 |
| Total Current Assets | 95,963 | 38,275 |
| Non-current Assets: | ||
| Operating lease right of use assets (Note 9) | 207 | — |
| Non-current prepaid expenses and other assets | 1,515 | 2,483 |
| Total Non-current Assets | 1,722 | 2,483 |
| Total Assets | $97,685 | $40,758 |
| Liabilities, Mezzanine Equity and Shareholders’ Equity | ||
| Current Liabilities: | ||
| Trade payables | $1,659 | $2,386 |
| Accrued expenses (Note 8) | 4,119 | 4,381 |
| Employee-related obligations | 1,645 | 2,372 |
| Liability for employee severance benefits | — | 206 |
| Operating lease liabilities (Note 9) | 115 | — |
| Total Current Liabilities | 7,538 | 9,345 |
| Long-term Liabilities: | ||
| Non-current operating lease liabilities (Note 9) | 99 | — |
| Other liabilities | 1,313 | — |
| Total Long-term Liabilities | 1,412 | — |
| Total Liabilities | 8,950 | 9,345 |
| Commitments and Contingencies (Note 11) | ||
| Mezzanine Equity: | ||
| Convertible Preferred Stock: $0.0001 par value; 20,000,000 shares authorized at December 31, 2023 and December 31, 2022; Series A Preferred Stock: 0 and 3,000 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively (Note 12) | — | 211 |
| Shareholders' Equity: | ||
| Preferred stock: $0.0001 par value; 20,000,000 shares authorized at December 31, 2023 and December 31, 2022, respectively; no shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively | — | — |
| Common stock: $0.0001 par value; 150,000,000 shares authorized at December 31, 2023 and December 31, 2022; 14,098,888 and 3,229,704 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively | 1 | — |
| Additional paid-in capital | 780,044 | 693,937 |
| Accumulated other comprehensive income | 26 | — |
| Accumulated deficit | (691,336) | (662,735) |
| Total Shareholders' Equity | 88,735 | 31,202 |
| Total Liabilities, Mezzanine Equity and Shareholders’ Equity | $97,685 | $40,758 |
F - 2
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.